



1/35



**HCV E2 proteins detected
with mMab E2G**

FIG. 1

BEST AVAILABLE COPY



Sequences amplified from central region of HCV E2 vaccinia virus clones

>hcv-1a3, (Q1a)

CTCAACTGGATTACCCAAAGTGTGGGAGCGCCCCCTGTGTCATGGAGGGGGGG
CAACAACACCTT GCGCTGCCCCACTGATTGTTCCGCAAGCATCCGGAAGCCAC
GTACTCTCGGTGCGGCTCCGGTCCCTGGATTACGCCCAAGGTGCCCTGGTC

>hcv-1b8, (Q1b)

TGGCACAGGGTTCACCAAGACGTGTGGGGCCCCCATGTACATCGGGGGGTCCG
CAATAACACCTT GACTTGGCCCCACGGACTGTTCCGGAAGCACCCCGAGGCCAC
TTACACCAAAATGTGTTCCGGGGCCTTGGCTGACACCTAGGTGCATAGTt

>hcv-2a-25, (Q2a)

CTCCACTGT TTCACCAAAACTTGGGGCGGCACCACCCTGCGGCATCAGAGCTGACTT
TAATGCCAGCACggaacctgctgtgccccacggactgttcaggaagcatcctgaagccac
TTACATCAAATGTGGCTCTGGGCCctgtgacgccaagtgcctgata

>HCV-2B-1, (Q2b)

TGGGACTGGGTTCACTAAGACATGGGGTGCACCACCCTTGCCGCAATTAGGAGGGACTG
CAACGGAAACCTcgacctattgtgccccacagactgtttcagaaagcacccagatactac
CTACCTTAAGTGTGAGCGGGGCTTGGTTGACCCCCCAAAATGCATGgTa

FIG. 2



3/35

Name	Sequences
HCV-1a	CTCAACTGGA TTCACCAAG TGTGGGAGC GCCTCCTTGT GTATCGGAG GGGCGGCAA
HCV-Q1a-FRGT...GA C.....G C..C..G... AA.....G... ..TC..T..
HCV-1b	TAGT.....GT...GA C.....G C..C..G... AA.....G... ..TC..T..
HCV-Q1b-FR	TGGC..A..GGA C...T..G.. C..C..A... AA.....G... ..TC.....
HCV-2a	...C.....C .A.....GA CT.....C.. A..A..C..C CG...TA... CT.ACTT...
HCV-Q2a-FR	...C.....-TA CT.....C.. A..A..C..C CG...A... CT.ACTTT...
HCV-2b	.GGG.....GT..GA CA.....T.. A..A.....C CG...TA.GA AA.ACTA...
HCV-Q2b-FR	TGGG.....GT..GA CA.....T.. A..A.....C CG...TA.GA ...ACT....
HCV-1a	CAACACC--- ---CTGCACT GCCCCTGA TTGCTTCCGC AAGCATCCGG ACGCCACATA
HCV-Q1a-FRT...G... ..T.....G... ..T.....G... ..T.....G...
HCV-1b	.CG.....T...AT... ..G...C.....G... ..C..C..G..T..T..
HCV-Q1b-FR	T.....T...ACT... ..G...C..T.....G... ..C..C..G...T..
HCV-2a	TGC..G.ATG GACT..TTG.G..C..T..TA.G... ..T..TA....C..
HCV-Q2a-FR	TGC..G.ACG GAC...TG.G..C..T..A.G... ..T..A....T..
HCV-2b	..G...TATC GATT.ATTG.A..C..T..TA.G... ..C..A..T..T..C..
HCV-Q2b-FR	.GGA...CTC GAC.ATTG.A..C..T..A.A... ..C..A..TA.T..C..

FIG. 3A

Name

Sequences

HCV-1a	CTCTCGGTGC	GGCTCCGGTC	CCTGATCAC	ACCCAGGTGC	CTGGTC
HCV-Q1a-FRT..	G.....
HCV-1b	.A.AAAA..TG..G.T.G..	...T.....	..A..A
HCV-Q1b-FR	.A.CAAA..T	.T..G..G.	.T..C.G..	..T.....	A.A..T
HCV-2a	.ATCAAA..TT..G.C....	G..A.....	...A..
HCV-Q2a-FR	.ATCAAA..TT..G.	..CT..-G..	G..A.A....	...A.A
HCV-2b	TCT.AA...T	.AG.A..G.	.T..T.A..	T.....	...A
HCV-Q2b-FR	.CT.AA...T	.AG.G..G.	.T..T.G..	C...AA...	A...A

One most parsimonious tree found:




FIG. 3B

5/35






FIG. 4A

6/35






FIG. 4B

Reactivity obtained with 12 HCV 2b Sera





FIG. 5

Binding Analysis of HCV HMABs



- Coat plates with GNA lectin
- Add E2 containing protein extracts
- Add MAb
- Detect bound Ab with anti Human-AP

FIG. 6



9/35




FIG. 7



10/35





FIG. 8A



11/35









FIG. 8B







FIG. 9



13/35

Competition Analysis



- Coat plates with GNA lectin
- Add E2 containing protein extracts

- Add competing MAb
- Add biotinylated Test HMab
- Detect bound Ab with Strep-AP

FIG. 10



14/35

CBH 5 Competition Analysis




FIG. 11



CBH 2 Competition Analysis




FIG. 12



16/35

CBH 7 Competition Analysis





FIG. 13


17/35

Binding to CD81-E2 complex




- Coat plates with GST-CD81-LEL or GST
- Add E2 containing protein extracts
- Add MAb
- Detect bound Ab with anti Human-AP

FIG. 14




18/35

FIG. 15




19/35

Inhibition of HCV virion binding to CD81



- Coat beads with CD81
- Combine serum with known amount of HCV virions with test HCV HMAb
- Incubate with beads
- Pellet & wash beads
- Detect bound HCV virions by quantitative PCV (Taqman)

FIG. 16



20/35




FIG. 17

Inhibition of HCV 1a E2 binding to GNA & CD81





FIG. 18



22/35





FIG. 19

23/35



Competition Assays



- Coat plates with GNA lectin
- Capture full-length intracellular E2 onto microtiter plate by binding CHO moieties to GNA lectin
- Mix competing HMAb with GNA-captured E2
- Add biotinylated test HMAb. Detect binding of biotinylated test HMAb to E2 with streptavidin-AP conjugate
- Inhibition of binding of test HMAb suggests epitopes within same antibody binding domain

FIG. 20

24/35

Competition Analysis of 4 HCV HMABs




FIG. 21A

25/35

Competition Analysis of 4 HCV HMABs




FIG. 21B



26/35

Summary of HMab Competition Analysis

Competitor Grp HMab		GROUP I				GRP II	GROUP III	
		CBH 2	CBH 5	CBH 8C	CBH 11	CBH 7	CBH 4G	CBH 4B
I	CBH 2	1a 18 1b 17	39 50	51 50	ND 48	93 91	66 84	76 84
	CBH 8E	1a 13 1b 23	39 45	48 57	ND 51	79 91	63 87	80 78
	CBH 5	1a 17 1b 4	9 7	22 24	ND 9	71 77	60 76	74 80
	CBH 8C	1a 27 1b 11	48 23	25 33	ND 23	85 84	74 87	84 86
	CBH 11	1a 96 1b 24	93 25	84 43	ND 25	97 82	72 97	87 83
II	CBH 7	1a 40 1b 104	42 104	45 89	ND 92	2 2	251 146	11 36

FIG. 22A

27/35

XTL U68		1a	60	63	108	ND	0	1	2
		1b	39	57	73	66	0	23	9
III	CBH 4G	1a	107	95	85	ND	112	40	68
		1b	87	83	81	87	114	40	44
	CBH 4B	1a	92	92	87	ND	85	24	29
		1b	78	93	66	81	63	34	13
	CBH 4D	1a	98	86	90	ND	135	37	58
		1b	91	82	76	87	102	45	37
IV	CBH 17	1a	94	87	87	ND	114	102	103
		1b	73	101	88	95	92	89	64
C	R04	1a	98	91	92	ND	101	92	98
		1b	96	104	104	101	99	120	101

Scale  >140%  60%-140%  30%-59%  10%-29%  <10%

Results are the mean percent binding of test antibody relative to wells without any competing antibody. Results are the mean values obtained from 2-5 separate experiments. Both genotype 1a and 1b E2 proteins were tested. ND = not done.

FIG. 22B



HCV E2 Deletion Constructs




FIG. 23

29/35

HCV E2 Deletion Constructs are efficiently expressed





FIG. 24

30/35

HCV E2 Deletion Constructs

HCV 1b E2 w or w/o HVR-1



HCV H1a E2 w or w/o HVR-1




FIG. 25A



31/35

HCV E2 Deletion Constructs





FIG. 25B

32/35

HCV sera have variable levels of antibodies
that inhibit CBH-2 & CBH-7




FIG. 26

33/35

HCV sera have variable levels of antibodies that inhibit CBH-2 & CBH-7





FIG. 27



34/35




FIG. 28



35/35




FIG. 29